MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LIVN stock logo

LIVN

LivaNova PLC

$79.97
0.56
 (0.71%)
Exchange:  NASDAQ
Market Cap:  4.393B
Shares Outstanding:  7.846M
Delayed data
Calculate LIVN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Vladimir A. Makatsaria
Full Time Employees:  3300
Address: 
5220 Valiant Court
Gloucester
GL
GL3 4FE
GB
Website:  https://www.livanova.com
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company’s products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/06 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,153,5451,253,4371,388,100
Gross Profit771,250870,873939,900
EBITDA38,483202,524-129,500
Operating Income-68,498129,051199,400
Net Income17,54663,234-242,500

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,429,5632,506,3892,606,100
Total Liabilities1,151,9351,186,1311,406,100
Total Stockholders Equity1,277,6281,320,2581,200,000
Total Debt640,404676,773425,000
Cash and Cash Equivalents266,504428,858635,600

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow74,914183,038254,300
Capital Expenditure-34,981-47,107-81,100
Free Cash Flow39,933135,931173,200
Net Income17,54663,234-242,500
Net Change in Cash62,254145,684-88,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,317,001.309Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,421,570.016Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,361,600Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)58,282.044Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)60,912.374Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)59,403.884Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)473,673.678Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)501,625.639Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)485,595.008Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,009,932.282Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,055,511.588Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,029,371.916Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)8.910Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)9.200Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)8.690Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.253B  ?P/S
 (TTM)
: 
2.94
?Net Income
 (TTM)
: 
63.234M  ?P/E
 (TTM)
: 
22.82
?Enterprise Value
 (TTM)
: 
4.161B  ?EV/FCF
 (TTM)
: 
28.05
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
15.41%  ?ROIC
 (TTM)
: 
10.19%
?Net Debt
 (TTM)
: 
-46783000  ?Debt/Equity
 (TTM)
: 
0.27
?P/B
 (TTM)
: 
3.27  ?Current Ratio
 (TTM)
: 
1.45

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
18.34Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates LIVN intrinsic value between $36.65 – $36.94 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about LIVN valuation

Is LivaNova PLC (LIVN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for LivaNova PLC (LIVN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LIVN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LIVN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LIVN’s P/E ratio?

You can see LIVN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LIVN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LIVN a good long-term investment?

Whether LIVN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

LIVN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.71
MARKETSnap

Trading Metrics:

Open: 79.83   Previous Close: 79.41
Day Low: 77.63   Day High: 80.03
Year Low: 48.82   Year High: 85.76
Price Avg 50: 80.47   Price Avg 200: 68.83
Volume: 733430   Average Volume: 755703

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
06-08-2026 13:36
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
05-08-2026 13:30
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova Q2 Earnings Call Highlights
05-08-2026 13:05
LivaNova Q2 Earnings Call Highlights
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
05-08-2026 10:16
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
05-08-2026 06:00
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
07-07-2026 10:20
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read